Related Experiment Video
Updated: Jun 16, 2026
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
[Clinical analysis on 28 cases of head-neck malignant fibrous histiocytoma]
Xin Lin1, Shaowen Zeng, Chu Yang
1Department of Otorhinolaryngology-Head and Neck Surgery, Shantou Central Hospital, the Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, 515031, China. lxlx2205@163.com
Objective:
To analyze the clinical feature and treatment of head-neck malignant fibrous histiocytoma (MFH).
Method:
A retrospective analysis on the clinical data of 28 cases of MFH were carried out, of which 9 were in the maxilla, 3 in the nasal cavity, 5 in the larynx, 3 in the parotid, 3 in the temporal bone, 1 in the hypothyroid, and 4 in the head and neck region. All of the cases underwent immune histochemistry: 4 cases of surgery alone, 23 cases of surgery followed by radiotherapy, and 1 case of radiotherapy alone.
Result:
Except 5 cases lost follow-up after 1 year, all the other cases were followed-up over 3 years, the survival rate for 1 or 3 years was respectively 96.4% (27/28) and 57.1% (16/28); 23 cases were followed up for 5 years, the survival rate was 26.1% (6/23). The recurrent rate in 3 years was 60.7% (17/28), with 1 to 7 times recurrence at a mean interval of 5.6 months. Twelve recurrent cases were adopted expanded resection of non-defined operation except 1 case with radiotherapy.
Conclusion:
The diagnosis of MFH depends on the technology of immune histochemistry. Early diagnosis, expanded resection, and integrated therapy could reduce the recurrence and increase the survival rate; the recurrence could adopt expanded resection of non-defined operation to prolong the life.